Tempest Therapeutics is a biotechnology business based in the US. Tempest Therapeutics shares (TPST) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $0.89 – a decrease of 19.1% over the previous week. Tempest Therapeutics employs 17 staff and has a market cap (total outstanding shares value) of 0.00.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $0.89 |
|---|---|
| 52-week range | $0.83 - $6.00 |
| 50-day moving average | $1.20 |
| 200-day moving average | $2.50 |
| Wall St. target price | $18.75 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-1.60 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $0.8899 from 2024-11-15
| 1 week (2024-11-11) | -19.10% |
|---|---|
| 1 month (2024-10-18) | -19.10% |
| 3 months (2024-08-16) | -38.20% |
| 6 months (2024-05-17) | -72.02% |
| 1 year (2023-11-17) | -74.28% |
|---|---|
| 2 years (2022-11-18) | -47.81% |
| 3 years (2021-11-18) | 10.81 |
| 5 years (2019-11-18) | 118.05 |
| Gross profit TTM | $0 |
|---|---|
| Return on assets TTM | -54.28% |
| Return on equity TTM | -289.26% |
| Profit margin | 0% |
| Book value | $1.21 |
| Market Capitalization | $24.5 million |
TTM: trailing 12 months
We're not expecting Tempest Therapeutics to pay a dividend over the next 12 months.
Tempest Therapeutics's shares were split on a 1:15 basis on 27 June 2021 . So if you had owned 15 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Tempest Therapeutics shares – just the quantity. However, indirectly, the new 1400% higher share price could have impacted the market appetite for Tempest Therapeutics shares which in turn could have impacted Tempest Therapeutics's share price.
Over the last 12 months, Tempest Therapeutics's shares have ranged in value from as little as $0.8312 up to $6. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Tempest Therapeutics's is -2.776. This would suggest that Tempest Therapeutics's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Tempest Therapeutics has bucked the trend.
Tempest Therapeutics, Inc. , a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat cancer; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors. It also develops TREX-1, an enzyme that regulates cGAS/STING pathway signaling and immune recognition. The company has agreement with Roche to advance the evaluation of amezalpat (TPST-1120) in combination with atezolizumab (Tecentriq®) and bevacizumab. Tempest Therapeutics, Inc. was incorporated in 2011 and is headquartered in Brisbane, California.
Robinhood Launches Presidential Election Event Contracts Ahead of the Nov 5 Presidential Election
Explore the best bonuses for opening a new brokerage account.
These are the best trading platforms for beginners, according to Finder’s comprehensive analysis.
Compare pros, cons, research tools and reviews for these two trading platforms.
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .
What you need to know about investing in the leading indicator for the overall US stock market.
Maximize $10,000 with broker bonuses, IRA contribution matches, index funds, stocks, ladder CDs, hiring a financial advisor and more.
Top ways to invest $20K include stocks, retirement accounts, conservative investments, ETFs and more. See our full list here.
A deep dive into the highlights and limitations of Robinhood.